This segment focuses on the research, development, and commercialization of innovative therapeutics for various dermatological conditions. VYNE Therapeutics is actively involved in clinical trials to evaluate the efficacy and safety of its product candidates. The company utilizes advanced technologies and methodologies to discover and develop novel treatments, including small molecules and topical formulations. The primary therapeutic areas include acne vulgaris, papulopustular rosacea, and atopic dermatitis. The company's products, such as AMZEEQ and ZILXI, aim to improve patient outcomes by reducing inflammation and improving skin health. VYNE Therapeutics is strategically positioned in the dermatology market, with a focus on unmet medical needs. Future opportunities include expanding the product pipeline and exploring partnerships to enhance market reach. Regulatory and clinical aspects are crucial, with a focus on obtaining FDA approval for new therapies. VYNE has partnerships with In4Derm Limited.

This segment encompasses research and development activities focused on immuno-inflammatory conditions, particularly within dermatology. VYNE Therapeutics is developing novel therapies, including oral BET inhibitors, to address unmet needs in this area. The company utilizes advanced research methodologies to identify and develop potential drug candidates. The therapeutic areas of focus include plaque psoriasis and vitiligo. The goal is to improve patient outcomes by targeting the underlying causes of inflammation. VYNE Therapeutics aims to gain a competitive advantage through its innovative approach to drug development. Future opportunities include expanding the pipeline and exploring collaborations. Regulatory and clinical aspects are critical, with a focus on obtaining FDA approval for new therapies. The company has a collaboration with In4Derm Limited.